PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
Authors
Keywords
-
Journal
ONCOGENE
Volume 30, Issue 29, Pages 3222-3233
Publisher
Springer Nature
Online
2011-03-02
DOI
10.1038/onc.2011.42
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations
- (2010) Shingo Dan et al. CANCER RESEARCH
- PI(3)King Apart PTEN's Role in Cancer
- (2010) S. Zhang et al. CLINICAL CANCER RESEARCH
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Genome remodelling in a basal-like breast cancer metastasis and xenograft
- (2010) Li Ding et al. NATURE
- A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
- (2010) Laura Poliseno et al. NATURE
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- mTOR signaling and drug development in cancer
- (2010) Janet Dancey Nature Reviews Clinical Oncology
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
- (2010) V. E. Kwitkowski et al. ONCOLOGIST
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
- (2010) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
- (2009) Britta Weigelt et al. BREAST CANCER RESEARCH AND TREATMENT
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
- (2009) Krishna M. Vasudevan et al. CANCER CELL
- PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
- (2009) R. J. Crowder et al. CANCER RESEARCH
- PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
- (2009) K. Kalinsky et al. CLINICAL CANCER RESEARCH
- mTOR and cancer: many loops in one pathway
- (2009) Alejo Efeyan et al. CURRENT OPINION IN CELL BIOLOGY
- The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo
- (2009) J. T. Huse et al. GENES & DEVELOPMENT
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
- (2009) X. Hu et al. MOLECULAR CANCER RESEARCH
- Everolimus
- (2009) Michael B. Atkins et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
- (2009) A Roidl et al. ONCOGENE
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
- (2008) Neil E. Torbett et al. BIOCHEMICAL JOURNAL
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells
- (2008) Ilya Serebriiskii et al. MATRIX BIOLOGY
- Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
- (2008) M Pickl et al. ONCOGENE
- Post-translational regulation of PTEN
- (2008) X Wang et al. ONCOGENE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
- (2008) Qing-Bai She et al. PLoS One
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Unraveling the microenvironmental influences on the normal mammary gland and breast cancer
- (2008) Britta Weigelt et al. SEMINARS IN CANCER BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More